Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2026 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM Announces Closing of Series B Extension Bringing Total Round to CHF 105 Million

NUCLIDIUM announced a CHF 26.4 million extension led by existing investors to accelerate clinical development of NU101 and NU201 radiotheranostic programs.
May 26, 2026 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence
May 21, 2026 07:30 ET | Source: EDAP TMS S.A.

EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference

, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Thursday, June 4th, 2026 AUSTIN,...
May 15, 2026 11:30 ET | Source: American Urological Association

Studies Highlight Personalized Approaches to Prostate Cancer Care, From Diet and Surgery to Public Awareness

WASHINGTON, DC, May 15, 2026 (GLOBE NEWSWIRE) -- From the foods men eat to how surgery is planned and public awareness unfolds, new research presented at the American Urological Association (AUA)...
May 14, 2026 09:17 ET | Source: Research and Markets

EpCAM-Targeted Immunotherapies Pipeline Competitor Analysis Report 2026: R&D Programs by R&D Phase and Profile of Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of EpCAM-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
May 14, 2026 09:12 ET | Source: Research and Markets

Her3-Targeted Immunotherapies Pipeline Competitor Analysis Report 2026: R&D Programs by R&D Phase and Profile of Her3-targeted Immunotherapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Her3-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
May 14, 2026 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026Announced...
May 14, 2026 08:00 ET | Source: Koelis

Koelis Announces ProMap® Smart Automatic Prostate Contouring Software at AUA 2026

KOELIS announces release of innovative ProMap® Smart automatic prostate contouring software at AUA 2026 in Washington, D.C.
May 14, 2026 07:30 ET | Source: EDAP TMS S.A.

EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer

, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited...
May 14, 2026 07:00 ET | Source: Profound Medical Corp.

Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative...